- Long-term outcome after surgery in a patient with intestinal Behçet’s disease complicated by myelodysplastic syndrome and trisomy 8
-
Mori Y, Iwamoto F, Ishida Y, Kuno T, Kobayashi S, Yoshida T, Yamaguchi T, Sato T, Sudo M, Ichikawa D, Enomoto N
- KMID: 2508580
- Intest Res.
- 2020 Oct;18(4):469-475.
- doi: 10.5217/ir.2019.09141
Behçet’s disease (BD) is a multisystem inflammatory disease of unknown origin. Rarely, BD occurs together with myelodysplastic syndrome (MDS). Interestingly, it is speculated that these are not simple coexistence but... -
- CITED
-
- Close
- SHARE
-
- Close
- Combination Therapy with Rituximab and Temozolomide for Recurrent and Refractory Primary Central Nervous System Lymphoma
-
Murakami M, Fujimaki T, Asano S, Nakaguchi , Yamada SM, Hoya K, Yamazaki K, Ishida Y, Matsuno A
- KMID: 1058828
- Yonsei Med J.
- 2011 Nov;52(6):1031-1034.
- doi: 10.3349/ymj.2011.52.6.1031
High-dose methotrexate-based chemotherapy has extended survival in patients with primary central nervous system lymphoma (PCNSL). However, although salvage treatment is necessary in recurrent and refractory PCNSL, this has not been... -
- CITED
-
- Close
- SHARE
-
- Close
- Dosimetric advantages and clinical outcomes of simultaneous integrated boost intensity-modulated radiotherapy for anal squamous cell carcinoma
-
Sakanaka K, Itasaka S, Ishida Y, Fujii K, Horimatsu , Mizowaki T, Sakai Y, Hiraoka M
- KMID: 2401791
- Radiat Oncol J.
- 2017 Dec;35(4):368-379.
- doi: 10.3857/roj.2017.00227
PURPOSE: The purpose of this study was to explore the dosimetric difference between simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) and three-dimensional conformal radiotherapy (3DCRT), and the clinical outcomes of anal... -
- CITED
-
- Close
- SHARE
-
- Close
